Evidence map›Paper›PMID 36169327›Full record

ArticleAntimicrobial agents and chemotherapy2022

Rodrigo E Mendes, Cory Hubler, J H Kimbrough, Valerie Kantro, Ian Critchley, Nicole Cotroneo, Mariana Castanheira

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. The oral penems and carbapenems.Clinical microbiology reviews · 2025
    Review
  3. Article
  4. Contemporary Evaluation of TebipenemMicrobiology spectrum · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rodrigo E MendesJMI Laboratoriesgrid.419652.d, North Liberty, Iowa, USA.ORCID 0000-0002-8648-1137
Cory HublerJMI Laboratoriesgrid.419652.d, North Liberty, Iowa, USA.ORCID 0000-0002-4927-0453
J H KimbroughJMI Laboratoriesgrid.419652.d, North Liberty, Iowa, USA.ORCID 0000-0002-0457-1543
Valerie KantroJMI Laboratoriesgrid.419652.d, North Liberty, Iowa, USA.ORCID 0000-0002-9178-1847
Ian CritchleySpero Therapeutics, Cambridge, Massachusetts, USA.ORCID 0000-0003-0981-0758
Nicole CotroneoSpero Therapeutics, Cambridge, Massachusetts, USA.ORCID 0000-0002-5267-4176
Mariana CastanheiraJMI Laboratoriesgrid.419652.d, North Liberty, Iowa, USA.ORCID 0000-0003-0126-1782

Funding

U.S. Department of Health and Human Services (HHS) HHSO100201800015C
6 · The paper itself

Abstract

This study investigated the activity of an oral carbapenem, tebipenem, against various molecularly characterized subsets of Escherichia coli. A total of 15.0% of E. coli isolates (360/2,035 isolates) met the MIC criteria for screening for β-lactamases. Most of those isolates (74.7% [269/360 isolates]) carried

Indexed as

Escherichia coli InfectionsEscherichia coli ProteinsUrinary Tract InfectionsAnti-Bacterial Agentsbeta-LactamasesCarbapenemsEscherichia coliHumansUnited StatesAnti-Bacterial Agentsbeta-LactamasesCarbapenemsEscherichia coli ProteinstebipenemcarbapenemsCTX-MESBLoralresistanceST131surveillance

Identifiers

PMID36169327
PMCPMC9578410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.